On April 1, 2026, Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced its acquisition of balipodect, a selective phosphodiesterase 10A (PDE10A) inhibitor, from Takeda. This acquisition grants Axsome exclusive global rights to develop balipodect for the treatment of schizophrenia and Tourette syndrome. The company plans to initiate Phase 3 trial-enabling activities for the schizophrenia indication later this year. The acquisition is expected to enhance Axsome's already robust neuroscience portfolio, which includes FDA-approved treatments for various CNS disorders. CEO Herriot Tabuteau expressed optimism about the potential of balipodect, highlighting its novel mechanism of action and relevance to multiple neuropsychiatric conditions. The deal includes an upfront payment to Takeda, along with additional payments tied to development and regulatory milestones, as well as royalties on future sales. Balipodect has shown promise in previous clinical trials, demonstrating a favorable safety profile and efficacy in treating schizophrenia. This strategic move positions Axsome to further solidify its leadership in the CNS market, addressing significant unmet medical needs in the treatment of serious mental health conditions.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.